With the potential to revolutionize clinical trial design and patient access to new treatments, the race is on to find markers that not only have diagnostic potential but prognostic and treatment-monitoring utility.
TORONTO (PRWEB) February 26, 2020
Join this live session on Wednesday, March 11, 2020 at 10:30 am EDT (2:30pm GMT/UK) with expert speakers Arun Sanyal, MD, Professor of Medicine at Virginia Commonwealth University (VCU) School of Medicine, Kenneth Cusi, MD, FACP, FACE, Professor of Medicine, Chief, at The University of Florida at Gainesville, and Claudia Filozof, MD, PhD, Vice President, Liver Therapeutic Area Head, Global Clinical Development at Covance.
The current, but imperfect, gold standard for diagnosis of NASH fibrosis is the liver biopsy. While liver biopsy allows pathologists to directly observe liver tissue, its utility in both clinical trials and clinical practice is limited. For example, in clinical development, primary endpoint data relies on just a small portion of the liver and is subject to sampling and central reader variability. In clinical practice, the invasive, costly and potentially painful and risky biopsy procedure is unlikely to gain widespread acceptance and use in the routine diagnosis of NASH fibrosis. With several therapeutics expected to reach the market soon, there is an urgent need to develop non-invasive biomarkers for the identification of patients at high risk for NASH fibrosis to ensure the right patients get the right treatment, at the right time.
While there is no shortage of promising blood- and imaging-based biomarker leads, the application of a non-invasive biomarker in NASH is still largely under development. With the potential to revolutionize clinical trial design and patient access to new treatments, the race is on to find markers that not only have diagnostic potential but prognostic and treatment-monitoring utility.
For more information or to register for this event, visit Non-Invasive Evaluation of Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis: Present and Future.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.